Clinical trial
A Prospective, Matched-Control, Randomized, Open-Label, Flexible-Dose, Study in Subjects With Recent-Onset Schizophrenia or Schizophreniform Disorder to Compare Disease Progression and Disease Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics
NCT02431702 is registered in ClinicalTrials.gov with Janssen Scientific Affairs, LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Matched-Control, Randomized, Open-Label, Flexible-Dose, Study in Subjects With Recent-Onset Schizophrenia or Schizophreniform Disorder to Compare Disease Progression and Disease Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics
- Lead sponsor
- Janssen Scientific Affairs, LLC
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- July 8, 2015
- Completion date
- November 12, 2019
- Enrollment
- 337 (actual)
- Sites
- 38
Conditions
As the registry lists them; a condition with its own page is linked.